fbpx Long Acting Buprenorphine injection for Opioid dependence; the CoLAB study | NDARC - National Drug and Alcohol Research Centre

Long Acting Buprenorphine injection for Opioid dependence; the CoLAB study

Image - Long Acting Buprenorphine injection for Opioid dependence; the CoLAB study
Date Published:
28 Nov 2019
Contact person:
Event date: 
Thursday, 28 November 2019 - 3:00pm

This seminar will provide an update on the CoLAB study - Community Study of Long Acting Buprenorphine Injection for Opioid Dependence.

About this Event

Opioid agonist treatment (OAT) for opioid dependence often emphasises supervised dosing, at least during early stages of treatment. Attendance for daily dosing is burdensome for patients and service providers, and newer extended-release buprenorphine (XR-BPN) injections represents a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate patient outcomes among people with opioid dependence receiving 12 months of XR-BPN treatment, and examines the implementation of XR-BPN in diverse community healthcare settings in Australia.

Speaker Bio:

Dr Jeyran Shahbazi completed her bachelor of advance science (Honours) and PhD at the school of Biotechnology and Biomolecular Sciences at UNSW. Her PhD involved characterisation and identification of the mechanisms contributing to oncogene amplification in childhood cancer, particularly neuroblastoma and leukaemia. Additionally, she investigated novel combination therapies targeting the potential causative pathways and performed in vitro and in vivo experiments to evaluate the treatment efficacies and underlying mechanism.

Following completion of PhD, Jeyran worked as research officer at Children`s Cancer Institute on characterising novel non-coding RNA in melanoma cells. Shortly after, she decided to pursue a career in clinical research to get a step closer to the patients and joined IQVIA (clinical research organisation) as Clinical Research Associate which involved 6 month of training program. During her time at IQVIA, Jeyran worked on multiple studies with new novel therapies to treat various disease such as flu, asthma, lupus, multiple sclerosis, kidney disease and prostate cancer and learned a great deal about conduct and operation of clinical trials. Jeyran joined National Drug and Alcohol Research Centre as Clinical Project Coordinator in September 2018 and has been managing conduct and operation of the CoLAB study.

Open to: 
Lecture Room 122, Building R1, 22 - 32 King St, Randwick, NSW 2031
Booking deadline: 
Thursday, 28 November 2019 - 3pm
Contact for bookings: 
Number of seats available: 
Contact for inquiries: